BGB-24714 / BeOne Medicines - LARVOL DELTA

BGB-24714-101: A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=157 | Active, not recruiting | Sponsor: BeiGene | Recruiting ➔ Active, not recruiting

Enrollment closed • Monotherapy • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BGB-24714-101: Study Investigating BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=229 | Recruiting | Sponsor: BeiGene | N=168 ➔ 229

Combination therapy • Enrollment change • Monotherapy • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BGB-24714-101: Study Investigating BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=168 | Recruiting | Sponsor: BeiGene | Trial completion date: Jul 2027 ➔ Nov 2026 | Trial primary completion date: Jan 2027 ➔ Dec 2025

Combination therapy • Monotherapy • Trial completion date • Trial primary completion date • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BGB-24714-101: Study Investigating BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors (clinicaltrials.gov) - P1 | N=168 | Recruiting | Sponsor: BeiGene | N=284 ➔ 168 | Trial completion date: Jan 2025 ➔ Jul 2027 | Trial primary completion date: Jul 2024 ➔ Jan 2027

Combination therapy • Enrollment change • Monotherapy • Trial completion date • Trial primary completion date • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BGB-24714, a novel oral IAP antagonist, displayed significant anti-tumor activities in preclinical models as a monotherapy and in combination with paclitaxel (AACR 2023) - P1 | "BGB-24714 effectively inhibited cIAP1 by inducing its degradation in MDA-MB-231 cells, with an EC50 of 2.5 nM. BGB-24714 also potently antagonized the inhibitory interaction of XIAP with caspase-9 and induced caspase-9 autoactivation in MDA-MB-231 cells, with an EC50 of 23 nM. In a total of 25 breast cancer cell lines treated with TNFα, BGB-24714 potently inhibited the in vitro proliferation of 5 breast cancer cells with EC50 < 100 nM."

Combination therapy • Monotherapy • Preclinical • Breast Cancer • Oncology • Solid Tumor • CASP9 • TNFA • XIAP

BGB-24714-101: Study Investigating BGB-24714 as Monotherapy and in Combination With Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=244 | Recruiting | Sponsor: BeiGene | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Monotherapy • Oncology • Solid Tumor

Study Investigating BGB-24714 as Monotherapy and in Combination With Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=244 | Not yet recruiting | Sponsor: BeiGene

Combination therapy • Monotherapy • New P1 trial • Oncology • Solid Tumor